Approval · Notice of Compliance 2568 · 2001
SEREVENT: Notice of Compliance 2568
Issued November 30, 2001
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 2568
- Date
- November 30, 2001
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Removal of indication: for use of adjunctive bornchodilator treatment for patients who have inadequate relief of symptoms with short-acting bronchodilators; product monograph revisions
- Therapeutic class
- Bronchodilator (beta2-adrenergic stimulant)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SEREVENT | Not yet assigned | — |
| SEREVENT DISKHALER DISK | Not yet assigned | — |
| SEREVENT DISKUS | Not yet assigned | — |
Medicinal ingredients
- SALMETEROL XINAFOATE 25 MCG per ACT
- SALMETEROL XINAFOATE 50 MCG per DOSE